Monthly Archives: July 2019

Genprex Begins Next Phase of Drug Branding Program

Genprex has initiated the first phase of branding its lead drug candidate and has completed the creation and submission of non-proprietary drug name selections to the American Medical Association’s United States Adopted Names (USAN) Council.

Read More

A Potential NSCLC Treatment for Large Patient Populations

Genprex is working on developing its initial drug candidate for NSCLC that would potentially benefit a large patient population who cannot currently benefit from approved therapies.

Read More

Genprex Provides Update on Development of its Oncoprex Immunogene Therapy in Combination With Immunotherapy for Non-Small Cell Lung Cancer

Genprex today provided an update on development of its lead drug candidate, Oncoprex™ immunogene therapy, in combination with immunotherapy for the treatment of non-small cell lung cancer (NSCLC).

Read More